Lanean...
Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer
The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free surv...
Gorde:
| Argitaratua izan da: | Cancer Biol Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7583699/ https://ncbi.nlm.nih.gov/pubmed/32844710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1809913 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|